How the Vaccine’s Immune Response May Disrupt Alzheimer’s Pathology

The biological link between shingles vaccination and reduced Alzheimer’s risk hinges on two mechanisms, according to Dr. Karen Duff, a neuroscientist at Columbia University’s Taub Institute for Research on Alzheimer’s Disease:

“The varicella-zoster virus (VZV) antigens in Shingrix trigger a robust Th1-mediated immune response. Preclinical work shows this can enhance microglial clearance of amyloid-beta peptides—something that fails in Alzheimer’s patients due to microglial dysfunction. Additionally, VZV infection itself has been associated with chronic neuroinflammation, so vaccinating against it may indirectly reduce low-grade brain inflammation, a known Alzheimer’s risk factor.”

—Dr. Karen Duff, PhD, Columbia University

Supporting this, a 2024 JAMA Neurology study found that herpes zoster (shingles) patients had a 2.5x higher amyloid burden on PET scans. The vaccine’s ability to prevent shingles may thus offer a dual benefit: direct neuroprotection and reduced amyloid accumulation.

Clinical caveat: While promising, these findings are correlational. A Phase III trial—currently in planning by the NIA—would need to confirm causality. “We’re not advocating for off-label use yet,” emphasizes Dr. Itzhaki. “But the signal is strong enough to justify urgent trials.”

What Happens Next: Trials, Guidelines, and Patient Access

The FDA has not yet updated its shingles vaccine guidelines to include Alzheimer’s prevention, but advocacy groups are pushing for change. The Alzheimer’s Association issued a statement calling for:

• Expanded access to Shingrix for adults 50+ as part of routine cognitive health screenings.
• Accelerated NIA-funded trials to test Shingrix in high-risk populations (e.g., APOE-ε4 carriers).
• Clarification that the vaccine is not a substitute for standard-of-care Alzheimer’s therapies (e.g., lecanemab).

Regulatory hurdles: The FDA’s Accelerated Approval pathway could fast-track trials if surrogate markers (e.g., amyloid PET reduction) are validated. However, pharma companies face liability risks if the vaccine’s dementia benefits are overstated.

Who Should Get the Vaccine—and When Should They Talk to a Specialist?

Current CDC recommendations already advise Shingrix for adults 50+ to prevent shingles. But the new Alzheimer’s data raises questions about who benefits most. Here’s how clinicians are advising:

• High-risk groups: Patients with family history of Alzheimer’s, APOE-ε4 genotype, or mild cognitive impairment (MCI) may see the greatest relative risk reduction. “[For these patients], the vaccine could be a low-cost, high-impact addition to their prevention plan,” says Dr. Kenneth Moskowitz, director of Yale’s Alzheimer’s Disease Research Unit.
• Timing: The protective effect appears strongest when administered before age 65, per subgroup analyses. Those over 70 saw a 22% reduction—still significant, but less pronounced.
• Contraindications: The vaccine is not recommended for immunocompromised individuals or those with a history of severe allergic reactions to vaccine components.

For patients considering the vaccine for Alzheimer’s prevention:

• Consult a board-certified neurologist to assess individual risk factors (e.g., amyloid burden via PET scan).
• Discuss with a geriatrician to balance benefits against potential side effects (e.g., myalgia, local reactions).
• Monitor cognitive function annually via specialized memory clinics if opting for the vaccine.

The Bigger Picture: Vaccines as a New Frontier in Alzheimer’s Prevention

This study adds to a growing body of evidence that infectious disease vaccines may influence brain health. Prior research has linked:

• The influenza vaccine to a 17% lower dementia risk (JAMA Neurology, 2021).
• The HPV vaccine to reduced neuroinflammation in animal models (Nature Aging, 2020).

Dr. Itzhaki’s work suggests vaccines may work by “resetting” the immune system’s trained immunity—a concept gaining traction in autoimmune and neurodegenerative research. “If we can harness the body’s existing immune machinery to target amyloid,” she says, “we might bypass the need for expensive biologics.”

Future directions: The NIA is exploring whether combination vaccines (e.g., shingles + flu) could offer synergistic benefits. Meanwhile, pharma companies are investigating VZV-derived therapeutics as direct Alzheimer’s treatments.

Where to Go for Specialized Care and Prevention

The shingles vaccine is widely available through primary care providers, but patients seeking Alzheimer’s-specific prevention strategies should consult specialists equipped to integrate emerging research into personalized plans. Consider these resources:

• [Relevant Clinic/Professional/Service]: Alzheimer’s Prevention Centers – Offer comprehensive risk assessments, including genetic testing and amyloid imaging, to tailor vaccine recommendations.
• [Relevant Clinic/Professional/Service]: Neuroimmunology Consultants – Can evaluate whether a patient’s immune profile (e.g., chronic inflammation) would benefit from Shingrix or alternative interventions.
• [Relevant Clinic/Professional/Service]: Clinical Trial Navigators – Help patients enroll in NIA-funded studies testing Shingrix for Alzheimer’s prevention, including the upcoming Phase III trial (estimated start: Q4 2026).

For healthcare providers looking to stay ahead of this evolving field:

• [Relevant Service]: Regulatory Compliance Attorneys – Can advise on updating informed consent protocols if Shingrix is prescribed off-label for cognitive protection.
• [Relevant Service]: Epidemiology Consulting Firms – Assist in designing post-marketing surveillance studies to monitor long-term dementia outcomes in vaccinated populations.